What's Kabir Nath's mailing address?
Kabir's mailing address filed with the SEC is C/O COMPASS PATHWAYS PLC, 33 BROADWICK STREET, LONDON, X0, W1F 0DQ.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at COMPASS Pathways plc
Over the last 3 years, insiders at COMPASS Pathways plc have traded over $12,645,913 worth of COMPASS Pathways plc stock. The most active insiders traders include George Jay Goldsmith, Ekaterina Malievskaia und Gino Santini. On average, COMPASS Pathways plc executives and independent directors trade stock every 32 days with the average trade being worth of $359,563. The most recent stock trade was executed by Ekaterina Malievskaia on 20 May 2024, trading 31,207 units of CMPS stock currently worth $246,535.
What does COMPASS Pathways plc do?
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.
What does COMPASS Pathways plc's logo look like?
COMPASS Pathways plc executives and stock owners
COMPASS Pathways plc executives and other stock owners filed with the SEC include:
-
George Jay Goldsmith,
Co-Founder, Chairman & CEO -
Dr. Ekaterina Malievskaia M.D.,
Co-Founder, Chief Innovation Officer & Exec. Director -
Lars Christian Wilde,
Sr. Advisor -
Dr. Susan C. Stansfield,
Sr. VP of Clinical Operations -
Dr. Greg Ryslik Ph.D.,
Sr. VP of Data Science, Machine Learning & Digital Health Research -
Trevor Mill,
Chief Devel. Officer -
Marco Mohwinckel,
Chief Commercial Officer -
Tracy Cheung,
Chief Communications Officer -
Stephen D. Schultz,
Sr. VP of Investor Relations -
Michael F. Falvey,
Chief Financial Officer -
Daphne Karydas,
Director -
Annalisa Jenkins,
Director -
David Y Norton,
Director -
Matthew A Owens,
General Counsel & CLO -
Guy Goodwin,
Chief Medical Officer -
Robert Mc Quade,
Director -
Thomas Lonngren,
Director -
Wayne Joseph Riley,
Director -
Kabir Nath,
Chief Executive Officer -
Michael Falvey,
Chief Financial Officer -
George Jay Goldsmith,
10% owner -
Ekaterina Malievskaia,
10% owner -
Mary Rose Hughes,
Interim CFO -
Teri Loxam,
Chief Financial Officer -
Gino Santini,
Director